Coverage
-
January 08, 2016
In a win for Merck, the Third Circuit has said it will weigh questions about the tolling standard established in a 1974 U.S. Supreme Court decision that led a New Jersey federal judge to preserve several fund investors' misrepresentation claims over the drugmaker's anti-cholesterol drug Vytorin.
3 other articles on this case.
View all »